Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Table 3

Diagnostic test evaluation of plasma mSEPT9 for CRC using 2/3 algorithm.

	mSEPT9	mSEPT9
Sensitivity (95% CI)	61.22% (51.33%–70.27%)	61.22% (51.33%–70.27%)
Specificity (95% CI)	98.42% (96.01%–99.38%)	93.70% (91.09%–95.57%)
PPV (95% CI)	93.75% (85.00%–97.54%)	67.42% (57.13%–76.26%)
NPV (95% CI)	86.76% (82.35%–90.20%)	91.90% (89.07%–94.04%)

PPV: positive predictive value; NPV: negative predictive value; CI: confidence interval; : mSEPT9 in subjects with colorectal cancer versus no evidence of diseases; : mSEPT9 in subjects with colorectal cancer versus all the other enrolled subjects including adenoma, noncolorectal cancer, inflammation, and no evidence of disease samples.